How to Get Actos (Pioglitazone) in Indiana

What Is Pioglitazone and Why Is It Prescribed?

Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer that the FDA approved in 1999 for type 2 diabetes mellitus. It activates peroxisome proliferator-activated receptor gamma (PPARγ), reducing insulin resistance in adipose tissue, skeletal muscle, and the liver. Takeda originally marketed it as Actos, but multiple generic manufacturers now produce it.

The drug is taken once daily as an oral tablet, typically at doses of 15 mg, 30 mg, or 45 mg. In the PROactive trial (N=5,238), pioglitazone reduced the composite of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% (HR 0.84, 95% CI 0.72 to 0.98) over a mean follow-up of 34.5 months [1]. That cardiovascular benefit distinguishes pioglitazone from several other oral diabetes medications.

Beyond type 2 diabetes, pioglitazone has gained traction as an off-label treatment for nonalcoholic steatohepatitis (NASH). The PIVENS trial (N=247) published in the New England Journal of Medicine in 2010 demonstrated that pioglitazone 30 mg daily significantly improved hepatic steatosis, lobular inflammation, and insulin resistance compared to placebo in patients with biopsy-confirmed NASH who did not have diabetes [2]. The American Association for the Study of Liver Diseases (AASLD) practice guidance lists pioglitazone as a pharmacotherapy option for NASH with or without diabetes [3].

For Indiana patients, both the diabetes and NASH indications are clinically relevant given that the state's adult diabetes prevalence reached 13.4% in 2022 according to the CDC's National Diabetes Statistics Report [4], and NAFLD/NASH prevalence tracks closely with obesity and metabolic syndrome rates that remain above the national average in Indiana.

Telehealth Prescribing in Indiana

Indiana permits telehealth prescribing of pioglitazone under the state's telehealth statute (IC 25-1-9.5), which authorizes licensed prescribers to establish a provider-patient relationship via synchronous audio-video consultation. No in-person visit is required before the first prescription.

This means an Indiana resident can schedule a video visit with a licensed physician, nurse practitioner, or physician assistant, receive an evaluation, and have a pioglitazone prescription sent electronically to any Indiana pharmacy. Several national telehealth platforms and Indiana-based practices offer metabolic health consultations that include TZD prescribing.

The prescriber must hold an active Indiana medical license (or multistate compact privilege) and document the clinical rationale. For off-label NASH use, the visit note should reference the AASLD guidance and the patient's imaging or biopsy findings. The consultation typically runs 15 to 30 minutes for an initial evaluation, and follow-up visits can be shorter.

One practical advantage of telehealth for pioglitazone is speed. Because the drug is a widely available generic, most pharmacies can fill the prescription same-day once the e-prescription arrives. Patients in rural Indiana counties, where endocrinology wait times can exceed 8 weeks, often find telehealth particularly useful for obtaining metabolic medications without a long referral chain.

Who Can Prescribe Pioglitazone in Indiana?

Indiana law allows physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs) to prescribe pioglitazone. The specific rules differ slightly by provider type.

Physicians (MD/DO): Full, independent prescriptive authority. No collaborative agreement needed. An internist, endocrinologist, family medicine physician, or hepatologist can prescribe pioglitazone for either diabetes or off-label NASH with no additional oversight requirement.

Nurse Practitioners (NP): Indiana NPs must have a collaborative agreement with a physician to prescribe. Under Indiana Code 25-23-1, an NP with prescriptive authority can prescribe pioglitazone as long as the collaborative agreement covers the relevant therapeutic category. This is standard for NPs practicing in primary care, endocrinology, or hepatology settings.

Physician Assistants (PA): PAs prescribe under a supervisory agreement with a physician. The supervising physician does not need to be physically present for each prescription, but the agreement must authorize prescribing in the drug's therapeutic class.

All three provider types can prescribe via telehealth. The choice of provider often comes down to availability and cost. According to a 2023 workforce analysis published by the Indiana State Department of Health, primary care NPs and PAs are more accessible than endocrinologists in 72 of Indiana's 92 counties [5]. For a straightforward pioglitazone prescription in a patient with established type 2 diabetes, a primary care NP or PA is a practical and appropriate choice.

Required Labs Before Starting Pioglitazone

The FDA-approved prescribing information for pioglitazone mandates liver function testing before initiation and periodically thereafter [6]. This requirement exists because troglitazone, an earlier TZD, was withdrawn from the market in 2000 due to hepatotoxicity. Pioglitazone has a much safer hepatic profile, but the FDA label retains the monitoring requirement.

Here is what your prescriber will order before writing the prescription:

• ALT (alanine aminotransferase): Pioglitazone should not be started if ALT exceeds 2.5 times the upper limit of normal. If ALT is between 1 and 2.5 times the upper limit, the prescriber may proceed with closer monitoring.
• HbA1c and fasting glucose: These establish the baseline glycemic status and help determine whether pioglitazone will be used as monotherapy or added to metformin, a sulfonylurea, or insulin.
• CBC and metabolic panel: Standard baseline labs for any new metabolic medication. Pioglitazone can cause fluid retention, so baseline kidney function and electrolytes are useful.
• Lipid panel: Pioglitazone raises HDL cholesterol and may raise LDL slightly. A baseline lipid panel helps track these changes.

For NASH-specific use, the prescriber may also order imaging (ultrasound with elastography or MRI-PDFF) or reference prior liver biopsy results. The AASLD guidance recommends a fibrosis assessment (FIB-4 index or vibration-controlled transient elastography) before starting pharmacotherapy for NASH [3].

Indiana has no state-specific lab requirements beyond what the FDA label mandates. Labs can be drawn at any CLIA-certified facility, including Quest Diagnostics and Labcorp locations throughout Indiana, or at hospital-based outpatient labs. Many telehealth providers will send a lab order to a location near the patient's zip code.

Indiana Pharmacy Options and 503A Compounding

Generic pioglitazone tablets are among the least expensive diabetes medications on the market. A 30-day supply of pioglitazone 30 mg typically costs $4 to $15 at major Indiana retail pharmacies, including CVS, Walgreens, Kroger, Walmart, and Meijer. The drug appears on most $4 generic lists.

Retail pharmacies: Any licensed Indiana pharmacy can dispense pioglitazone with a valid prescription. E-prescribing is the standard transmission method, so the prescription arrives at the pharmacy within minutes of the telehealth or in-person visit.

503A compounding pharmacies: Indiana licenses 503A compounding pharmacies under the Indiana Board of Pharmacy. These pharmacies can compound pioglitazone into alternative dosage forms (such as suspensions for patients who cannot swallow tablets) if a prescriber writes a patient-specific prescription. A 503A pharmacy compounds medications pursuant to an individual prescription, as distinct from 503B outsourcing facilities that produce larger batches. For standard oral tablet dosing, retail pharmacies are the most practical option. Compounding becomes relevant when the patient needs a non-standard dose or dosage form.

Mail-order and 90-day supply: Most pharmacy benefit managers (PBMs) and commercial insurers allow 90-day pioglitazone fills through mail-order pharmacies. For patients paying out of pocket, 90-day supplies from Costco or Amazon Pharmacy can bring the per-month cost below $4. GoodRx and similar discount platforms often list pioglitazone 30 mg at under $10 for 30 tablets at Indiana pharmacies.

The Endocrine Society clinical practice guideline on type 2 diabetes pharmacotherapy notes that cost-effectiveness is a valid factor in medication selection and that pioglitazone's generic pricing makes it one of the most affordable insulin sensitizers available [7].

Indiana Medicaid and Insurance Coverage

Indiana Medicaid (the Healthy Indiana Plan, or HIP) does not currently list pioglitazone on its preferred drug list for type 2 diabetes. This means Medicaid beneficiaries face a non-preferred status requiring prior authorization, or the drug may not be covered at all depending on the managed care organization (MCO) administering the benefit.

The three MCOs managing Indiana Medicaid (Anthem, CareSource, and MDwise) each maintain their own preferred drug lists. Patients should check their specific MCO formulary. If pioglitazone is listed as non-preferred, the prescriber can submit a prior authorization arguing medical necessity, particularly if the patient has failed or is intolerant to preferred agents like metformin.

Commercial insurance: Most commercial plans cover generic pioglitazone at the lowest (Tier 1) copay. Prior authorization is uncommon for the FDA-approved diabetes indication but may be required for off-label NASH use. The prior authorization typically requires documentation of:

1. A confirmed NASH diagnosis (biopsy or validated non-invasive testing)
2. Failure of or contraindication to lifestyle modification
3. Baseline liver function tests within acceptable range
4. Prescriber attestation citing published evidence (the PIVENS trial is the standard reference)

Medicare Part D: Generic pioglitazone is covered by virtually all Medicare Part D plans. The Centers for Medicare & Medicaid Services data show that pioglitazone was prescribed to approximately 1.2 million Medicare beneficiaries in 2023, making it one of the more commonly used branded-class generics in diabetes care [4].

For uninsured Indiana patients, the out-of-pocket cost of generic pioglitazone is low enough that discount programs often bring the monthly expense below the cost of a typical copay.

Prior Authorization Documentation for Indiana

When prior authorization is required, the process follows a predictable pattern. Indiana insurers and MCOs typically require the prescriber to submit a standardized prior authorization form (many accept the AMA's universal prior authorization form) along with supporting documentation.

The documentation package should include the patient's diagnosis (ICD-10 code E11.xx for type 2 diabetes, or K75.81 for NASH), recent lab values (HbA1c, ALT, fasting glucose), a list of previously tried and failed medications, and the prescriber's clinical rationale. For NASH, include imaging reports showing hepatic steatosis or fibrosis staging.

Turnaround times in Indiana vary by payer. State law requires urgent prior authorization decisions within 24 hours and standard requests within 72 hours for commercial plans. Indiana Medicaid MCOs follow similar timelines under their managed care contracts with the Indiana Family and Social Services Administration (FSSA).

A denied prior authorization can be appealed. The prescriber should include peer-reviewed citations. The PIVENS trial [2] and the AASLD practice guidance [3] are the two most persuasive references for off-label NASH appeals. For diabetes-related denials where a preferred agent was tried first, documenting the adverse effect or therapeutic failure with specific lab values strengthens the appeal.

Transferring a Pioglitazone Prescription to Indiana

Patients moving to Indiana or traveling within the state can transfer an existing pioglitazone prescription from an out-of-state pharmacy. Indiana Board of Pharmacy regulations permit prescription transfers for non-controlled substances (pioglitazone is not a controlled substance) between licensed pharmacies.

The process is straightforward. The patient contacts the receiving Indiana pharmacy and provides the name and location of the originating pharmacy. The pharmacist at the Indiana location calls the originating pharmacy to verify and transfer the prescription. Electronic transfer is also permitted. The transferred prescription retains its remaining refills.

For patients who have been receiving pioglitazone through an out-of-state telehealth provider, the provider can continue prescribing as long as they hold an Indiana license or the patient establishes care with an Indiana-licensed prescriber. Indiana does not have a specific reciprocity carve-out for out-of-state telehealth prescriptions, so the prescribing provider must be licensed in Indiana at the time the prescription is written.

Timeline: How Quickly Can You Get Pioglitazone in Indiana?

The total time from initial consultation to medication in hand depends on the route chosen. A realistic breakdown:

Telehealth route: Schedule a video consultation (often available within 1 to 3 days, sometimes same-day). The visit itself lasts 15 to 30 minutes. If labs are needed, add 1 to 2 days for the blood draw and results. Once the prescription is sent electronically, most Indiana pharmacies can fill pioglitazone within 1 to 2 hours. Total: 2 to 5 days from scheduling to first dose, assuming labs are needed. If the patient has recent labs (within 3 months), the prescription can be filled the same day as the telehealth visit.

In-person route: Scheduling an appointment with a primary care physician or endocrinologist may take 1 to 4 weeks depending on the provider's availability and location. Labs are often drawn at the same visit or ordered in advance. Prescription turnaround at the pharmacy is the same: 1 to 2 hours.

Prior authorization delay: If the insurer requires prior authorization, add 1 to 3 business days for the standard review. Urgent requests may be processed within 24 hours. Patients who pay out of pocket bypass prior authorization entirely.

The fastest path for a patient with recent labs and no insurance barriers is a same-day telehealth visit followed by same-day pharmacy pickup. Given pioglitazone's widespread availability as a generic, stock-outs are rare at Indiana pharmacies.

Safety Monitoring and Follow-Up

Once a patient starts pioglitazone, the FDA label recommends periodic liver function testing [6]. Most prescribers check ALT at 3 months, then every 6 to 12 months if results remain normal.

Other monitoring considerations include:

• Weight and edema: Pioglitazone can cause 2 to 4 kg of weight gain and peripheral edema. The PROactive trial reported edema in 21.6% of pioglitazone-treated patients versus 13.0% in the placebo group [1]. Patients with NYHA Class III or IV heart failure should not use pioglitazone.
• Bone density: Long-term TZD use is associated with decreased bone mineral density, particularly in postmenopausal women. A meta-analysis published in CMAJ found that TZDs increased fracture risk in women (OR 2.23, 95% CI 1.65 to 3.01) [8]. Prescribers may consider baseline DEXA scanning for at-risk patients.
• Bladder cancer concern: The FDA conducted a 10-year epidemiological review and concluded in 2016 that the data do not conclusively link pioglitazone to bladder cancer, though the labeling retains a mention of the signal [9]. Patients with active bladder cancer should not use the drug.

Indiana prescribers should ensure follow-up labs are accessible. For telehealth patients, follow-up visits can also be conducted via video, with lab orders sent to a local facility.

Off-Label NASH Use: What Indiana Patients Should Know

The PIVENS trial remains the landmark evidence for pioglitazone in NASH. In that study, 34% of pioglitazone-treated patients achieved resolution of NASH on follow-up biopsy compared to 19% of placebo-treated patients (P=0.04) [2]. A subsequent meta-analysis in Gastroenterology (N=516) confirmed that pioglitazone improves fibrosis, steatosis, and inflammation scores in NASH patients with and without diabetes [10].

For Indiana patients seeking pioglitazone for NASH, the prescribing pathway is the same as for diabetes. The key difference is insurance coverage. Off-label use triggers prior authorization with most payers, and Indiana Medicaid is unlikely to approve NASH as an indication. Out-of-pocket generic pricing ($4 to $15 per month) makes self-pay a viable alternative for many patients.

The recently approved resmetirom (Rezdiffra) is the first FDA-approved drug specifically for NASH with moderate-to-advanced fibrosis, but its cost exceeds $40,000 per year. Pioglitazone remains the most cost-effective pharmacotherapy option for NASH, and the AASLD guidance continues to list it as a recommended agent [3].

Patients on pioglitazone 30 mg daily for NASH should expect ALT improvements within 3 to 6 months and histological improvement by 18 to 24 months based on PIVENS data [2].